FDA Accepts sBLA for Daratumumab, Hyaluronidase-fihj for Treatment of Multiple Myeloma

Daratumumab and hyaluronidase-fihj in combination with other therapies was previously approved by the FDA in May 2020 for 8 indications in multiple myeloma.

Related Keywords

Darzalex Faspro ,Craig Tendler ,Janssen Biotech Inc , ,Biologics License Application ,Janssen Biotech ,Johnson Innovative Medicine ,